1
0
0
News
History of Changes for Study: NCT ClinicalTrials.gov
www.clinicaltrials.gov
Study Officials: Bengt Hoepken Study Director UCB Pharma. Locations: Germany. Schwarz Monheim, Germany. Open or close this module IPDSharing ... › NC...
Translational Immunology - the Node
thenode.biologists.com
— ... Martin Guilliams – VIB-UGent Center for Inflammation Research, BE; Pleun Hombrink – Sanquin, NL; Bengt Hoepken – Clinical Program ... › ev...
UCB (EBR:UCB) UCB Media Room: ACR Data Highlights
www.webdisclosure.com
— ... Robert Landewé, Martin Rudwaleit, Stephen Hall, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Brian Kilgallen, Désirée van der Heijde. › n...
Netzwerk-Profile
LinkedIn: Bengt Hoepken - Deutschland | LinkedIn
Bengt Hoepken. Senior Clinical Trial Manager at Schwarz Pharma Location Cologne Area, Germany Industry Pharmazie
LinkedIn: Bengt Hoepken | LinkedIn
Bengt Hoepkens berufliches Profil anzeigen LinkedIn ist das weltweit größte berufliche Netzwerk, das Fach- und Führungskräften wie Bengt Hoepken dabei hilft, ...
Es fehlt: essen ruhr
LinkedIn: Bengt Hoepken | LinkedIn
Bengt Hoepkens berufliches Profil ... wie Bengt Hoepken dabei hilft, interne ...
LinkedIn: Bengt Hoepken - Deutschland | LinkedIn
Sehen Sie sich das Karriere-Profil von Bengt Hoepken (Deutschland) auf LinkedIn an. LinkedIn ist das weltweit größte professionelle Netzwerk, das Fach- und ...
Interessen
UCB Presents New Long-Term Data Showing PR Newswire
www.prnewswire.com
— ... Robert Landewé, Martin Rudwaleit, Stephen Hall, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Brian Kilgallen, Désirée van der Heijde. › ucb...
Improvements in extraarticular manifestations of psoriatic arthritis...
www.em-consulte.com
Journal of the American Academy of Dermatology - Vol N° 5S1 - p. AB Improvements in extraarticular manifestations of psoriatic arthritis over...
Limited radiographic progression and sustained reductions in MRI...
ard.bmj.com
... Natasha de Peyrecave UCB Celltech, Slough, UK PubMed articlesGoogle scholar articles; Bengt Hoepken UCB Pharma, Monheim, Germany PubMed articlesGoogle scholar articles; Lars Bauer UCB Pharma, Monheim, Germany PubMed articlesGoogle scholar articles; Tommi Nurminen UCB Pharma, ...
Effect of certolizumab pegol on dermatologic outcomes over 96 weeks...
www.em-consulte.com
Philip Mease, MD, Swedish Medical Center and University of Washington, Seattle, WA, United States; Bengt Hoepken, UCB Pharma, Monheim am Rhein, ...
Management & Beteiligungen
Ucb SA - MarketVisual Knowledge Map
www.marketvisual.com
Bengt Hoepken, Researcher PAST show details and sources... GeneralEmployment (Researcher) [Past] · Benoit Debecker, Technology EXPLORATION ...
UCB - MarketVisual Knowledge Map
www.marketvisual.com
Aki Nagatomi, RECRUITER show details and sources... GeneralEmployment (RECRUITER) · Bengt Hoepken, Researcher PAST show details and sources.
Bücher
Induction of sustained clinical remission in early axial ...
biblio.ugent.be
von R Landewe · · Zitiert von: 10 — ... Filip Van den Bosch, Karl Gaffney, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Karen Thomas, and Lianne S. Gensler › publication
Karen Thomas | 3 Publications | 17 Citations | Related Authors
typeset.io
Bengt Hoepken. 44 papers, 1.2K citations. 97% related. Xenofon Baraliakos papers, 17.5K citations. 96% related. Désirée van der Heijde. › authors
Posttranslationale Regulation der cytosolischen Phospholipase A 2 in...
books.google.de
Bengt Höpken pages. 0 Reviewshttps://books.google.com/books/about/Posttranslationale_Regulation_der_cytoso.html?id=Zd3akQEACAAJ ...
Dokumente zum Namen
Certolizumab Pegol Efficacy in Patients With Non ...
onlinelibrary.wiley.com
von PC Robinson · — Bengt Hoepken,. Bengt Hoepken. UCB Pharma, Monheim am Rhein, Germany. 1Philip C. Robinson, MBChB, PhD: University of Queensland School of ... › acr2
Certolizumab pegol treatment in axial spondyloarthritis ...
academic.oup.com
von X Baraliakos · · Zitiert von: 1 — Xenofon Baraliakos, Sebastian Kruse, Simone E Auteri, Natasha de Peyrecave, Tommi Nurminen, Thomas Kumke, Bengt Hoepken, Jürgen Braun, Certolizumab pegol ... › article-...
Limited radiographic progression and sustained - ScienceOpen
www.scienceopen.com
von J Braun · — natasha de peyrecave,7 Bengt Hoepken,8 Lars Bauer,8 tommi nurminen,8. Juergen Braun9. AbstrACt. Objectives to report 4-year imaging outcomes. › PubMedCentral
Wissenschaftliche Veröffentlichungen
Predictors of long-term clinical response in patients with non ...
arthritis-research.biomedcentral.com
von WP Maksymowych · · Zitiert von: 1 — Thomas Kumke, Bengt Hoepken & Lars Bauer. UCB Pharma, Milan, Italy. Simone E. Auteri. University of Bielefeld, Klinikum Bielefeld, ... › ...
Veröffentlichungen allgemein
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of ...
core.ac.uk
von A Deodhar · — Robert Landewé,6 Martin Rudwaleit,7 Stephen Hall,8 Lars Bauer,9 Bengt Hoepken,9 Natasha de Peyrecave,10. Brian Kilgallen,11 and Désirée van ... › download › pdf
Certolizumab Pegol Treatment in Patients with Axial Springer
link.springer.com
von IE van der Horst-Bruinsma · — Mindy Kim, Thomas Kumke, Lars Bauer, and Bengt Hoepken: employees and stockholders of UCB Pharma. Atul Deodhar: speaker for Janssen, ... › article
Artikel & Meinungen
Translational Immunology - | Nature Careers
www.nature.com
Martin Guilliams. VIB-UGent Center for Inflammation Research, BE. Pleun Hombrink. Sanquin, NL. Bengt Hoepken. Clinical Program Director, UCB Pharma, DE. › event
Sonstiges
(PDF) 4-year results from the RAPID-PsA phase 3 randomised ...
www.academi.live
Bengt Hoepken. Download Free PDF View PDF. Open Access Rheumatology: Research and Reviews. An evidence-based review of certolizumab pegol in the treatment ... › 4_year...
4-Year Results from the RAPID-PsA Phase 3 Randomised ...
touroscholar.touro.edu
von D van der Heijde · · Zitiert von: 34 — Dafna Gladman,5 Alice B Gottlieb,6 Bengt Hoepken,7 Lars Bauer,7. Oscar Irvin-Sellers,8 Majed Khraishi,9 Luke Peterson,10 Anthony Turkiewicz, ... › cgi › viewcontent
47. Kongress der Deutschen Gesellschaft für Rheumatologie ...
www.egms.de
von VSA Raleigh — ... Elisabeth Kleine - UCB Pharma GmbH, Monheim; Bengt Hoepken - UCB Pharma GmbH, Monheim; Nicola Goodson - Aintree University Hospital, ... › meetings › dgrh2019
ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND ...
researchportal.bath.ac.uk
von LC Coates · · Zitiert von: 1 — Laura C. Coates, Joseph F. Merola, Oliver Fitzgerald, Arthur Kavanaugh, Alice B. Gottlieb, William Tillett, Lars Bauer, Bengt Hoepken, ... › a...
C2-Junioren - Blau-Gelb Überruhr
www.blau-gelb-ueberruhr.de
Trainer: Bengt Höpken (T: – ). Trainer: Guido Peschke (T: – ). . › Mannschaft › C2...
1 Long Term Safety of Rituximab in Rheumatoid Arthritis Clinical...
docplayer.net
... Portland); Dafna Gladman (University of Toronto, Toronto); Christian Stach (Brussels); Bengt Hoepken (Brussels); Luke Peterson (Brussels); Désirée van der ...
Certolizumab Pegol Treatment in Patients with Axial PubMed
pubmed.ncbi.nlm.nih.gov
von IE van der Horst-Bruinsma — ... Philip C Robinson , Ennio G Favalli , Frank D Verbraak , Mindy Kim , Thomas Kumke , Lars Bauer , Bengt Hoepken , Atul Deodhar ... › ...
5th Annual Optimizing Clinical Trials. Barcelona, 9th - 10… | Flickr
www.flickr.com
... Department / Teva Turkey Bengt Hoepken / Associate Clinical Program Director / UCB Carmen Prenn-Gologranc / Head of Section Clinical Scales / Lundbeck ...
Content Posted in | Providence St. Joseph Health Digital ...
digitalcommons.psjhealth.org
... Dafna Gladman, Alice B Gottlieb, Bengt Hoepken, Lars Bauer, Oscar Irvin-Sellers, Majed Khraishi, Luke Peterson, Anthony Turkiewicz, Jürgen Wollenhaupt, ... › ...
A One-Year Placebo-Controlled Study in Non-Radiographic Axial...
www.researchsquare.com
Results from the C-axSpAnd trial, in which patients with active non-radiographic axial spondyloarthritis and inadequate response to at least two NSAIDs showed...
Dr. med. Thomas Rath, MSc - Fachklinik Bad Bentheim
www.fk-bentheim.de
Irene E. van der Horst-Bruinsma, Rianne E. van Bentum, Frank Verbraak, Atu l Deodha, Thomas Rath, Bengt Hoepken, Oscar Irvin-Sellers, Karen Thomas, ... › rheumatologie › vita-rath
Effect of certolizumab pegol over 96 weeks of treatment on ...
discovery.ucl.ac.uk
von J Braun · · Zitiert von: 31 — Pedro M Machado,4 Walter P Maksymowych,5 Owen Davies,6 Bengt Hoepken,7. Tommi Nurminen,7 Christian Stach,7 Désirée van der Heijde8. To cite: Braun J,. › e full.pdf
Dr. Mark Hwang, MD – Houston, TX | Rheumatology
www.doximity.com
Bengt Hoepken, Daniel Serrano, Kristina Harris, Mark C. Hwang, John D. Reveille> ;Quality of Life Research Mar 1.
Irene van der Horst-Bruinsma,1 Rianne E. van Bentum,1 ...
www.medfyle.com
Frank D. Verbraak,1 Thomas Rath,2 Bengt Hoepken,3. Oscar Irvin-Sellers,4 Thomas Kumke,3 Lars Bauer,3. Martin Rudwaleit5. AAU: acute anterior uveitis; ... › articles › download_file
GMS | 42. Kongress der Deutschen Gesellschaft für...
www.egms.de
... Science University, Arthritis & Rheumatic Diseases, Portland, United States of America; Bengt Hoepken - UCB Pharma GmbH, Monheim ...
Induction of sustained clinical remission in early axial...
research-portal.uea.ac.uk
... Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch, Karl Gaffney, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Karen Thomas, Lianne S Gensler.
Long-term safety and clinical outcomes of certolizumab pegol ...
accounts.public.ce.basespace.illumina.com
... Walter P Maksymowych, Robert Landewé, Martin Rudwaleit, Lars Bauer, Thomas Kumke, Mindy Kim, Simone Emanuele Auteri, Bengt Hoepken, Atul Deodhar. › ...
Poster podcasts - ACR Highlights 2020
rheumhighlights.com
Irene van der Horst-Bruinsma, Rianne van Bentum, Frank Verbraak, Thomas Rath, James Rosenbaum, Bengt Hoepken, Oscar Irvin-Sellers, Thomas Kumke, ... › pod...
Orthopedics & Sports Medicine | Clinical Institutes & Areas of...
digitalcommons.psjhealth.org
... Filip Van den Bosch, Jürgen Braun, Philip Mease, Alan J Kivitz, Jessica Walsh, Owen Davies, Lars Bauer, Bengt Hoepken, Luke Peterson, and Atul Deodhar ...
Verwandte Suchanfragen zu Bengt Höpken
| Lars Bauer Gabriele Höpken |
Person "Höpken" (1) Vorname "Bengt" (543) Name "Höpken" (180) |
sortiert nach Relevanz / Datum